

cbdMD's VP of Scientific & Regulatory Affairs to Speak on a Panel Regarding Safety Standards for Dietary Ingredients

CHARLOTTE, N.C. — September 9, 2021 — cbdMD, Inc. (NYSE American: YCBD, YCBDpA) (the “Company”), one of the leading, and most highly trusted and recognized cannabidiol (CBD) brands, announced that Dr. Sibyl Swift, Vice President for Scientific & Regulatory Affairs, will be speaking at the Consumer Healthcare Products Association’s (CHPA) Regulatory, Scientific & Quality meeting on September 10, 2021. CHPA is a consumer healthcare industry trade association which fights for consumer access to OTC medicines, consumer medical devices and dietary supplements. Dr. Swift will be presenting on a panel of industry and FDA experts that will cover key aspects of safety substantiation in FDA submissions and how these processes can be improved.

The speakers during this session will be discussing New Dietary Ingredient Notifications (NDINs), generally recognized as safe (GRAS) notifications, and independent conclusions of GRAS (self-GRAS) pathways. Dr. Swift’s presentation will provide the key stakeholder perspective of a former FDA official who now works for an industry leading cannabinoid company.

“We are excited that Dr. Swift was invited to participate at this meeting. She is an integral part of the Company’s scientific work in support of world-wide regulatory submissions. Her participation and insights are examples of the Company’s continued commitment to providing its consumers with products that meet the highest regulatory standards for quality and safety” said Martin Sumichrast, Chairman & Co-CEO of cbdMD, Inc.

About cbdMD, Inc.

cbdMD, Inc. is one of the leading, most highly trusted health and wellness CBD companies, whose current products include CBD tinctures, CBD capsules, CBD gummies, CBD topicals, CBD botanical skincare products, CBD bath bombs and CBD pet products. To learn more about cbdMD and our comprehensive line of over 100 SKUs of U.S. produced, THC-free¹ CBD products, please visit www.cbdMD.com, follow cbdMD on [Instagram](#) and [Facebook](#), or visit one of the 6,000 retail outlets that carry cbdMD products.

Forward-Looking Statements

This press release contains certain forward-looking statements that are based upon current expectations and involve certain risks and uncertainties within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking statements can be identified by the use of words such as "should," "may," "intends," "anticipates," "believes," "estimates," "projects," "forecasts," "expects," "plans," and "proposes." These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, some of which are beyond our control and difficult to predict. You are urged to carefully review and

consider any cautionary statements and other disclosures, including the statements made under the heading "Risk Factors" in cbdMD, Inc.'s Annual Report on Form 10-K for the fiscal year ended September 30, 2020 as filed with the Securities and Exchange Commission (the "SEC") on December 22, 2020 and our other filings with the SEC. All forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements, many of which are generally outside the control of cbdMD, Inc. and are difficult to predict. cbdMD, Inc. does not undertake any duty to update any forward-looking statements except as may be required by law. The information which appears on our websites and our social media platforms, including, but not limited to, Instagram and Facebook, is not part of this press release.

¹ THC-free is defined as below the level of detection using validated scientific analytical tools.

Contacts

PR:

cbdMD, Inc.

Robert Pettway

Director of Digital Media

rpettway@cbdmd.com

423-503-5225

Investors:

cbdMD, Inc.

John Weston

Director of Investor Relations

john.weston@cbdmd.com

704-249-9515